Developmental and epileptic encephalopathies (DEEs) make up a diverse range of conditions that generally present with significant epileptic seizures and electroencephalogram (EEG) abnormalities. DEEs can significantly impact children and adults living with the condition, as well as caregivers. Patients within the community are frequently burdened by challenges associated with diagnostic delay, missed diagnoses, and disparities which present as barriers to timely interventions and treatment. Further complicating diagnosis, Lennox-Gastaut Syndrome (LGS) may have variable presentations that change over time. To optimize care for patients with DEEs such as LGS, clinicians must have knowledge of the most recent clinical trial data and real-world studies on novel therapies and utilize collaborative care practices that includes long-term care discussions among the interprofessional healthcare team.
This CMEO “Snack” will offer clinicians the chance to learn from expert faculty, informed upon by real-world unmet needs identified among HCPs, patients, and caregivers, including topics such as identifying the impact of DEEs on patients, incorporating the latest clinical trial data and real-world evidence to individualize treatment plans for patients with LGS, and integrating a collaborative approach to therapeutic decision-making.
At the conclusion of this activity, learners will be able to better:
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Primary: Neurologists, physician associates (PAs), and nurse practitioners (NPs)
Secondary: Pediatricians and primary care providers
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-0000-24-048-H01-P).
This activity is designated for 0.75 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 08/30/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Thiele reports the following financial relationships:
Advisory Board and Consultant: Aditum Bio; Azurity; Biocodex; Jazz Pharmaceuticals, Inc.; LivaNova; Nobelpharma; Stoke Therapeutics; Takeda; and UCB Pharma
Grants and Research Support: Biocodex; Jazz Pharmaceuticals, Inc.; and UCB Pharma
Dr. Thomas reports the following financial relationships:
Advisory Board: Jazz Pharmaceuticals, Inc.; Neurelis, Inc.; and SK Life Science, Inc.
Consultant: Jazz Pharmaceuticals, Inc. and SK Life Science, Inc.
Speakers Bureau: Jazz Pharmaceuticals, Inc.; Neurelis, Inc.; and SK Life Science, Inc.
The following individuals have no financial relationships to disclose:
Jeffrey Helfand, DO (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer reviewer)
Evan Luberger (Planning Committee)
Erin Spencer, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
SN-246-083024-43